Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)
Artikel i vetenskaplig tidskrift, 2018

Objective: To evaluate variables associated with hemoglobin A1c (HbA1c) and weight reduction when adding liraglutide to persons with type 2 diabetes treated with multiple daily insulin injections (MDI). Research design and methods This was a reanalysis of a previous trial where 124 patients were enrolled in a double-blind, placebo-controlled, multicenter randomized trial carried out over 24 weeks. Predictors for effect on change in HbA1c and weight were analyzed within the treatment group and with concurrent interaction analyses. Correlation analyses for change in HbA1c and weight from baseline to week 24 were made. Results The mean age at baseline was 63.7 years, 64.8% were men, the mean number of insulin injections was 4.4 per day, the mean daily insulin dose was 105 units and the mean HbA1c was 74.5 mmol/mol (9.0%). The mean HbA1c and weight reductions were 12.3 mmol/mol (1.13%; P < 0.001) and 3.8 kg (P < 0.001) greater in liraglutide than placebo-Treated persons. There was no significant predictor for greater effect on HbA1c that existed in all analyses (univariate, multivariate and interaction analyses against controls). For a greater weight reduction when adding liraglutide, a lower HbA1c level at baseline was a predictor (liraglutide group P=0.002, P=0.020 for liraglutide group vs placebo). During follow-up in the liraglutide group, no significant correlation was found between change in weight and change in HbA1c (r=0.09, P=0.46), whereas a correlation existed between weight and insulin dose reduction (r=0.44, P < 0.001). Conclusion Weight reduction becomes greater when adding liraglutide in patients with type 2 diabetes treated with MDI who had a lower HbA1c level compared with those with a higher HbA1c level. There was no correlation between reductions in HbA1c and weight when liraglutide was added, that is, different patient groups responded with HbA1c and weight reductions. Trial registration number EudraCT nr: 2012-001941-42.

weight

liraglutide

predictive variables

HbA1c

Författare

S. Dahlqvist

NU-sjukvården

Elsa Ahlén

Värnamo sjukhus

Göteborgs universitet

NU-sjukvården

Karin Filipsson

Skånes universitetssjukhus (SUS)

Lunds universitet

Thomas Gustafsson

Karolinska universitetssjukhuset

Irl B. Hirsch

University of Washington

Jaakko Tuomilehto

King Abdulaziz University

National Institute for Health and Welfare

Dasman Diabetes Institute

Henrik Imberg

Chalmers, Matematiska vetenskaper, Tillämpad matematik och statistik

Statistiska Konsultgruppen

Bo Ahrén

Lunds universitet

Stig Attvall

Göteborgs universitet

Marcus Lind

NU-sjukvården

Göteborgs universitet

BMJ Open Diabetes Research and Care

2052-4897 (eISSN)

Vol. 6 1 e000464

Ämneskategorier

Endokrinologi och diabetes

Annan klinisk medicin

Näringslära

DOI

10.1136/bmjdrc-2017-000464